Singapore
Singapore’s Ignition AI Accelerator partners Pfizer to advance biopharma sector with AI. Ignition AI Accelerator, a collaborative initiative between NVIDIA, Tribe, and Digital Industry Singapore (DISG), has announced a a strategic partnership with global biopharmaceutical leader Pfizer to advance biopharma sector with artificial intelligence (AI).
Tribe said in a statement on Wednesday that the Singapore-backed Ignition AI Accelerator aims to advance AI capabilities and expand applications across industries, driving global startup innovation.
The partnership with Pfizer will leverage Ignition AI Accelerator’s extensive network in Southeast Asia—including media, government, universities, accelerators, tech talent, and investors—to accelerate drug discovery and research processes, bringing innovative treatments to market faster, said the statement.
It is noted that the Singapore government has been seeking to actively leverage and advance frontier technologies such as AI to support its biomedical science and healthcare ecosystems, and to enhance the quality of healthcare in Singapore.
In addition to fostering private-public sector partnerships, it has invested over $25 billion in science and technology research as part of its Research, Innovation and Enterprise (RIE) 2025 plan.
Through the collaboration with DISG, Ignition AI Accelerator serves to attract top international AI startups to Singapore, building a thriving ecosystem for frontier technologies.
Concurrently, the accelerator also empowers startups to expand geographically to scale abroad and accelerate their go-to-market strategies.
According to the statement, the collaboration with Pfizer further positions Ignition AI Accelerator at the nexus of AI, and empowers local ecosystem partners and biomedical startups with the scale and expertise of these industry giants.
Through these partnerships in the healthcare sector, Ignition AI Accelerator is better positioned to foster the development of groundbreaking therapies, patient care and services, and advancing precision medicine globally.
“We are excited to collaborate with Pfizer, one of the leading players in the biopharmaceutical industry,
“Our collaborative goal is to empower these pharmaceutical giants with the latest advancements in AI to drive innovation in drug discovery and development,” said Ng Yi Ming, Chief Executive Officer, Tribe.
According to him, this partnership underscores their commitment to accelerating breakthroughs that can significantly impact lives globally.
It is noted that Pfizer is at the forefront of leveraging AI to transform drug discovery and development processes.
By integrating into the Ignition AI network, Pfizer aims to create faster, better content to communicate with stakeholders, enable a more efficient patient drafting system and improve the yields and cycle times in the manufacturing process.
“AI is reshaping the landscape of pharmaceutical research, and our partnership with the Ignition AI Accelerator by Nvidia and Tribe is a step forward in our commitment to harnessing these technologies to advance our communications with patients and healthcare professionals,
“With access to a thriving startup ecosystem, we are looking forward to catalysing groundbreaking biomedical startups and poised to accelerate innovations in stakeholders’ engagement in the industry,” said Bei Goh, Regional Client Partner Lead, Emerging Asia at Pfizer.
Tribe is a global innovation partner dedicated to building vibrant ecosystems for emerging technologies such as artificial intelligence and blockchain.
The firm collaborates with high-potential startups, leading corporations across different sectors, and governments to accelerate the adoption and implementation of cutting-
edge technologies.
